New diabetes pill shows promise in major trial

NCT ID NCT01413204

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called TA-7284 in 272 adults with type 2 diabetes. Participants took either a low dose, high dose, or a placebo pill daily for 24 weeks. The goal was to see if the drug safely lowers blood sugar levels (measured by A1C) compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TA-7284 (an experimental oral drug for lowering blood sugar)
What this could lead to: If it works, this could offer a new daily pill option to help people with type 2 diabetes better control their blood sugar levels.
What could go wrong: This is a completed Phase 3 trial, but results are not yet widely known. The drug may not prove more effective than existing treatments, and side effects like hypoglycemia or other risks are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Show contact details

Locations

Reserch site

Chūbu, Japan
Reserch site

Kanto, Japan
Reserch site

Kinki, Japan
Reserch site

Shikoku, Japan
Reserch site

Tōhoku, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.